When I review an AI system, I want to understand what decision its evaluation supports. Are we deciding whether to launch, whether to replace an existing system, or whether a research direction deserves more investment? Those questions require different evidence.
Teams can usually explain which benchmarks they track. It is often harder to establish what result would change their plans. An improvement demonstrates progress, but it may leave the deployment question unanswered.
I have encountered this across clinical AI, content systems, and enterprise applications: a model performs well on the selected benchmark, yet users remain reluctant to rely on it. Sometimes the benchmark is sound. It simply measures something different from what users need to trust.
Consider a hypothetical clinical extraction system. Aggregate accuracy could improve while the system becomes worse at identifying a rare but important finding. Whether that tradeoff is acceptable depends on the workflow: who reviews the output, what happens when the finding is missed, and whether the system can abstain. The aggregate score cannot answer those questions by itself.
This is why I want the decision defined before the evaluation is designed. What are we proposing to let the system do? Which failures would make that unacceptable? What evidence would establish that it is ready?
The development team brings knowledge of model behavior and measurement. Domain experts bring knowledge of consequential errors. The people using the system understand review burden and how failures affect their work. Someone also needs to own the decision and its tradeoffs.
I find launch gates useful when they are agreed before results arrive. Otherwise, it is easy to choose a threshold that accommodates the system we have already built. A gate should specify what happens when the evidence falls short: delay deployment, narrow the use case, require additional review, or reconsider the approach.
Research benchmarks still matter. They help compare methods, diagnose weaknesses, and track progress. I want that work connected to a second question: what additional evidence do we need before acting on the result?
The question I keep returning to in reviews is: if this result were worse, what would we do differently? If the answer is unclear, we may have a useful reporting metric. We still have work to do before it can guide the decision.
What I was reading
This note draws on my experience reviewing evaluation across clinical AI, content systems, and enterprise applications. The clinical extraction example is illustrative.